文献速递消化道肿瘤放疗胸部肿瘤放疗

颈段与上胸段食管癌根治性放(化)疗剂量递增的多中心回顾性研究(ChC&UES)

Dose escalation in radical radio(chemo)therapy for cervical and upper thoracic esophageal cancer with 3DCRT/IMRT (ChC&UES): a multicenter retrospective study.
PubMed 文献 · Radiat Oncol · 2024-09-27

这项多中心回顾性研究分析了1422例颈段与上胸段食管癌患者,按原发肿瘤放疗剂量分为标准剂量组(50-55 Gy)和高剂量组(>55 Gy),高剂量组再分为常规高剂量组(55-63 Gy)和超高剂量组(≥63 Gy)。高剂量放疗在颈段食管癌中显著改善生存,但在上胸段食管癌中未显示生存获益,且骨髓抑制风险更高;进一步剂量递增至≥63 Gy未改善生存但提高了客观缓解率。

要点

  • 高剂量放疗在颈段食管癌中显著改善生存(多因素P=0.024),上胸段无显著获益(P=0.735)。
  • 常规高剂量与超高剂量在颈段和上胸段食管癌中生存均无显著差异(P=0.976、0.610)。
  • 超高剂量较标准剂量提高颈段与上胸段食管癌的客观缓解率(P<0.05),但骨髓抑制风险更高(P=0.039)。

核心结论

  • 高剂量放疗对颈段食管癌有生存获益,对上胸段食管癌无生存获益,同时增加骨髓抑制风险。
  • 进一步剂量递增至≥63 Gy未改善生存,但提高了客观缓解率。

研究设计与样本

  • 多中心回顾性研究(ChC&UES),纳入8个医学中心共1422例颈段与上胸段食管癌病例。
  • 按原发肿瘤放疗剂量分为标准剂量组(SD,50-55 Gy)和高剂量组(HD,>55 Gy),高剂量组再分为常规高剂量组(HD-conventional,55-63 Gy)和超高剂量组(HD-ultra,≥63 Gy)。
  • 主要终点为总生存期(OS)。

主要发现

  • 全队列中位OS为33.0个月(95%CI:29.401-36.521)。
  • 颈段食管癌中,高剂量组较标准剂量组在Kaplan-Meier分析(P=0.029)和Cox多因素回归分析(P=0.024)中均显示生存显著改善。
  • 上胸段食管癌中,高剂量组与标准剂量组生存相当(P=0.735)。
  • 颈段食管癌中常规高剂量组与超高剂量组生存无显著差异(P=0.976),上胸段食管癌中两组亦无显著差异(P=0.610)。
  • 高剂量组放射性食管炎和肺炎发生率与标准剂量组相当(P=0.097、0.240),但骨髓抑制风险更高(P=0.039)。

关键数值与推荐

  • 标准剂量放疗定义为原发肿瘤剂量50-55 Gy,高剂量放疗定义为>55 Gy。
  • 高剂量放疗进一步分为常规高剂量(55-63 Gy)和超高剂量(≥63 Gy)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical and upper thoracic esophageal cancer (ESCA) presents treatment challenges due to limited clinical evidence. This multi-center study (ChC&UES) explores radical radio(chemo)therapy efficacy and safety, especially focusing on radiation dose. METHOD: We retrospectively analyzed clinical data from 1,422 cases across 8 medical centers. According to the radiation dose for primary gross tumor, patients were divided into standard dose radiotherapy (SD, 50-55 Gy) or high dose (HD, > 55 Gy) radiotherapy. HD was further subdivided into conventional- high-dose group (HD-conventional, 55-63 Gy) and ultra-high-dose group (HD-ultra, ≥ 63 Gy). Primary outcome was Overall Survival (OS). RESULTS: The median OS was 33.0 months (95% CI: 29.401-36.521) in the whole cohort. Compared with SD, HD shown significant improved survival in cervical ESCA in Kaplan-Meier (P = 0.029) and cox multivariate regression analysis (P = 0.024) while shown comparable survival in upper thoracic ESCA (P = 0.735). No significant difference existed between HD-conventional and HD-ultra in cervical (P = 0.976) and upper thoracic (P = 0.610) ESCA. Incidences of radiation esophagitis and pneumonia from HD were comparable to SD (P = 0.097, 0.240), while myosuppression risk was higher(P = 0.039). The Bonferroni method revealed that, for both cervical and upper thoracic ESCA, HD-ultra enhance the objective response rate (ORR) compared to SD (P < 0.05). CONCLUSION: HD radiotherapy benefits cervical but not upper thoracic ESCA, while increasing bone marrow suppression risk. Further dose escalating (≥ 63 Gy) doesn't improve survival but enhances ORR.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao XH, Zhang WC, Wang X, et al. Dose escalation in radical radio(chemo)therapy for cervical and upper thoracic esophageal cancer with 3DCRT/IMRT (ChC&UES): a multicenter retrospective study. Radiat Oncol. 2024. PMID: 39334163. doi:10.1186/s13014-024-02521-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。